Clinical Review

The 2026 Springer review establishes tirzepatide as a genuine multi-organ metabolic integrator: its dual GIP/GLP-1 receptor co-agonism simultaneously reshapes adipose lipolysis, hepatic lipid flux, skeletal muscle glucose uptake, and pancreatic beta-cell function. The net body composition result is 22 to 25 percent total weight loss with approximately 75 percent attributable to fat mass, outperforming semaglutide monotherapy in comparative analyses.

A 2026 review in Saudi Medical Journal (PMC13227446) confirms semaglutide delivers clinically meaningful glycaemic control, 15 to 17 percent body-weight reduction, approximately 20 percent cardiovascular risk reduction, and emerging hepatic and renal benefits. The critical performance caveat is lean-mass attrition of 30 to 40 percent of total weight lost, demanding deliberate resistance-training and protein-intake countermeasures.